The Weekly Recap 6/6/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni enter new partnerships, secure new funds, achieve regulatory milestones, and much more on the road to LSI Asia ’25 in Singapore (June 10–13).

3DBioFibR

Raised $3M in equity financing to expand manufacturing capacity, pursue ISO 13485 certification, and support commercial growth of its advanced biopolymer fiber platform. The investment enables 3DBioFibR to meet growing demand across medical, defense, and consumer sectors with high-performance, clinically relevant biomaterials.

AliveCor

Announced a year-long partnership with the British Heart Foundation to support cardiovascular research through cause-related donations tied to KardiaMobileⓇ 6L sales in the UK. The campaign unites AliveCor’s AI-powered ECG technology with the charity’s legacy in scientific research to advance early detection and treatment of heart conditions.

BiVACOR

Received FDA Breakthrough Device Designation for its Total Artificial Heart (TAH) system, designed as a bridge-to-transplant solution for patients with severe biventricular or univentricular heart failure. The designation accelerates BiVACOR’s clinical development of its compact, magnetically levitated heart replacement technology.

Clairity

Received FDA De Novo authorization for CLAIRITY BREAST, the first AI platform authorized to predict five-year breast cancer risk from a screening mammogram alone. The milestone positions Clairity’s image-based solution to transform early detection and personalized prevention strategies for women’s health.

Corify Care

Announced a new know-how agreement with Mayo Clinic to refine Corify Care’s AI-powered cardiac mapping system for arrhythmia treatment. The partnership aims to enhance clinical workflow and procedural guidance, accelerating adoption of Corify’s noninvasive, real-time global mapping technology for complex heart rhythm disorders.

MDsim

Secured €2.3M in oversubscribed seed funding led by Kadmos Capital to launch SPINEsim, MDsim’s first Software as a Medical Device for personalized spine surgery planning and back pain prevention. The funding will accelerate development of patient-specific digital twin technologies aimed at improving outcomes and reshaping the future of spine care.


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-6625-lsi-alumni-achievements-driving-medtech-and-healthtech-forward 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more